Goldman Sachs’s Tonix Pharmaceuticals TNXP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.02M Buy
104,487
+6,131
+6% +$72.4K ﹤0.01% 5227
2026
Q2
$1.26M Buy
98,356
+45,301
+85% +$585K ﹤0.01% 5040
2026
Q1
$730K Buy
53,055
+26,247
+98% +$404K ﹤0.01% 5325
2025
Q4
$419K Buy
26,808
+14,086
+111% +$260K ﹤0.01% 5702
2025
Q3
$307K Buy
+12,722
New +$472K ﹤0.01% 5735
2022
Q4
– Sell
-2
Closed -$18K – 6270
2022
Q3
$18K Buy
2
+1
+100% +$24.5K ﹤0.01% 5956
2022
Q2
$17K Hold
1
– – ﹤0.01% 6202
2022
Q1
$98K Hold
1
– – ﹤0.01% 6115
2021
Q4
$219K Hold
1
– – ﹤0.01% 5849
2021
Q3
$371K Buy
+1
New +$487K ﹤0.01% 5370
2021
Q2
– Hold
0
– – – 6100
2021
Q1
– Hold
0
– – – 5395
2017
Q1
– Hold
0
– -$46K – 7003
2016
Q4
– Hold
0
– – – 6407
2016
Q3
– Hold
0
– – – 6854
2016
Q2
– Hold
0
– – – 6646
2014
Q1
– Hold
0
– -$109K – 6933
2013
Q4
– Hold
0
– – – 6247

Other funds holding TNXP

Goldman Sachs's TNXP Position: Q3 2026 in Review

Goldman Sachs increased its Tonix Pharmaceuticals (TNXP) stake by 6.2% in Q3 2026, buying an estimated $72.4K and bringing the position to 104,487 shares worth $1.02M. The position accounts for ﹤0.01% of the portfolio, ranked #5227.

Goldman Sachs first reported a position in TNXP in Q3 2021 and has held it in 10 quarters since. The position peaked at $1.26M in Q2 2026. 113 funds tracked by Wall St. Rank hold TNXP as of Q3 2026.

  • Goldman Sachs held 104,487 shares of Tonix Pharmaceuticals worth $1.02M as of Q3 2026.
  • Goldman Sachs bought 6,131 Tonix Pharmaceuticals shares in Q3 2026, an estimated $72.4K.
  • Tonix Pharmaceuticals made up ﹤0.01% of Goldman Sachs's portfolio in Q3 2026, its #5227 holding.
  • Goldman Sachs first reported a position in Tonix Pharmaceuticals in Q3 2021 and has held it in 10 quarters since.
  • Goldman Sachs's Tonix Pharmaceuticals position peaked at $1.26M in Q2 2026.
  • 113 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q3 2026.

Based on Goldman Sachs's 13F filing for Q3 2026, filed 16 Nov 2026.